Abilita Therapeutics
3210 Merryfield Row
San Diego
California
92121
United States
Tel: 858-437-9357
Website: http://www.abilitabio.com/
Email: info@ablitabio.com
About Abilita Therapeutics
Abilita Bio was founded in June 2014 and is an innovation-driven biotechnology company focused on enabling discovery and development of drugs targeting challenging membrane proteins, including G Protein-Coupled Receptors (GPCRs) and ion channels.
YEAR FOUNDED:
June 2014
LEADERSHIP:
Founder and CEO: Mauro Mileni, PhD
COO: Randy Schreckhise
CTO: Rosario Billetta, DSc
Vice President, Innovation: Christopher B. Roth, PhD
JOBS:
Please click here for Ablita Bio job opportunities.
PIPELINE:
Please click here for Abilita Bio's pipeline.
8 articles about Abilita Therapeutics
-
Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer
6/1/2023
Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the company changed its name to Abilita Therapeutics.
-
Abilita Bio Appoints Dan Bradbury to its Newly Formed Board of Directors
2/23/2022
Abilita Bio, Inc., today announced the appointment of Daniel M. Bradbury to its Board of Directors.
-
Abveris and Abilita Bio Announce a Discovery Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets
8/24/2021
Abveris, Inc. ("Abveris") and Abilita Bio, Inc. announce a joint research collaboration that will leverage the synergies between their platforms to enable the discovery of novel antibodies targeting key GPCRs within the tumor immune microenvironment.
-
Abilita Bio Announces Business Growth and Key DevelopmentsShift to discovery of proprietary programs facilitated by increased resources, infrastructure and capabilities
1/9/2020
Abilita Bio, Inc., an innovation-driven biotechnology company focused on enabling discovery and development of drugs targeting challenging membrane proteins, today announced a series of corporate updates that includes an expansion of scientific scope, personnel, and infrastructure.
-
Abilita Bio and Amgen Enter Into a Multi-Target Collaboration
2/13/2019
Research collaboration will focus on the generation of novel Enabled Membrane Proteins (EMPs™) to support R&D efforts on challenging drug targets
-
X-Chem and Abilita Bio Announce a Joint Research Collaboration
12/13/2017
Under the terms of the agreement, Abilita will generate EMPs for several high-value GPCR and ion-channel targets, which will be screened by X-Chem using its proprietary DEX libraries to identify agonists and/or antagonists, as dictated by the target biology and desired mechanism of action.
-
Abilita Bio Signs A New Research Collaboration With A Global Pharmaceutical Company And 2016 Milestone Review
1/31/2017
-
Abilita Bio Awarded NCI Phase-I SBIR Grant To Develop Therapeutic Antibodies Targeting Metastatic Breast Cancer
9/20/2016